Page 2 - தாக்கம் ஆஃப் வடமேற்கு பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vaccine Safety for Kids 6 Months and Up Last week, Pfizer and BioNTech announced that in a Phase 3 trial in adolescents 12 to 15 years of age, “the Pfizer-BioNTech COVID-19 vaccine demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated.”   “We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. “We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.”

Cook countyUnited statesNorthwestern universityUnited kingdomAlbert bourlaCenters for diseaseImpact of northwestern universityJohns hopkins university medicine coronavirus resource centerWorld health organizationHarvard global health instituteIllinois department of pubic healthEvanston health human services departmentRisk of communityMetrics for school determination of communityEdmondj safra centerThresholds for community transmission